Previous investigations have identified an overrepresentation of the luminal A molecular subtype, a subtype known for lower rates of pCR while maintaining a good prognosis, in HER2-low cancers [8, 18], which explains the poor response to chemotherapy in the HER2-low group. Here, ERBB2 is linked to cancer.